hiv-1

Documents about hiv-1

• Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]#860581ClinicalTrials.gov
• A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs#882619ClinicalTrials.gov
• The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children#910258ClinicalTrials.gov
• Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance#474886ClinicalTrials.gov
• Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis#867575ClinicalTrials.gov
• Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life#1009215ClinicalTrials.gov
• KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)#900595ClinicalTrials.gov
• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1#826473ClinicalTrials.gov
• Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects#879134ClinicalTrials.gov
• Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children#916592ClinicalTrials.gov
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.#441964ClinicalTrials.gov
• Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)#869723ClinicalTrials.gov
• Cannabidiol prevents mucosal HIV-1 transmission by targeting Langerhans cells, dendritic cells, macrophages and T-cells#137403HAL (France)
• Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients#886982ClinicalTrials.gov
• Factors associated with severity of pulmonary tuberculosis in people living with and without HIV: a systematic review#354005HAL (France)
• Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy#904358ClinicalTrials.gov
• A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults#904398ClinicalTrials.gov
• The Biology of HIV Transmission#994889ClinicalTrials.gov
• Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial#339582bioRxiv / medRxiv
• Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)#831422ClinicalTrials.gov
• The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation#839215ClinicalTrials.gov
• Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)#850648ClinicalTrials.gov
• Rifaximin as a Modulator of Microbial Translocation and Immune Activation#871104ClinicalTrials.gov
• Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients#872211ClinicalTrials.gov
• HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study#912819ClinicalTrials.gov
• Cabotegravir for preventing HIV-1 in adults and young people#2381NCBI Bookshelf
• Mapping the vRNA Interaction with HIV-1 Integrase#329315bioRxiv / medRxiv
• Lipopeptide Immunisation With GTU-multiHIV Trial#454062ClinicalTrials.gov
• HSV Oral Reactivation in Children#890739ClinicalTrials.gov
• Gut-Associated Lymphocyte Trafficking#994514ClinicalTrials.gov
• Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3#805403ClinicalTrials.gov
• Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV-1-infected Patients Treated With Bictegravir#879654ClinicalTrials.gov
• A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers#982577ClinicalTrials.gov
• Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication#646727Repisalud
• A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants#883658ClinicalTrials.gov
• Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients#846251ClinicalTrials.gov
• A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers#321541ClinicalTrials.gov
• A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)#902000ClinicalTrials.gov
• A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells#898685ClinicalTrials.gov
• Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission#174935ClinicalTrials.gov
• Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1#834398ClinicalTrials.gov
• CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy#839980ClinicalTrials.gov
• Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation#844144ClinicalTrials.gov
• ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla#1008978ClinicalTrials.gov
• Long-Term Data Collection From Participants in Adult AIDS Clinical Trials#893700ClinicalTrials.gov
• Chronic THC exposure modulates behavioral outcomes and endocannabinoid signaling in HIV-1 Tg26 mice in a sex-dependent manner#435141UNC Dataverse Dataverse OAI Archive
• Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage#853748ClinicalTrials.gov
• A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients#805829ClinicalTrials.gov
• A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults#992730ClinicalTrials.gov
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults#350000ClinicalTrials.gov